Advertisement

WST

West Pharmaceutical Services, Inc.

Healthcare · USD

Set alert

Price alert · WST

All alert types
412.62 USD -4.05 -0.97%
As of Oct 30, 2026 Extended hours 412.62 0.00%
Bid
411.54 × 200
Ask
412.97 × 200
407.67 Day range 422.08
230.95 52-week range 416.67
YTD
+49.97%
1 year
+48.14%
Open
419.06
Prev close
416.67
Mkt cap
28.79B
Vol
1.06M
Avg vol
571.74K
EPS
7.81
P/E
52.83
Div yield
0.25%
More statistics
Low
407.67
High
422.08
Forward P/E
41.31
Beta
0.00
Short ratio
3.38
Inst. own
102.49%
Dividend
1.04
Ex-div date
Nov 9, 2026
Earnings
Feb 11, 2027
50-d avg
366.43
200-d avg
312.69
1y target
442.20

MAX chart

Chart tools
Interval
WST all-time price chart2.19120.5238.8357.1475.4Dec 84Jun 93Sep 01Mar 10Jun 18Oct 26

Key statistics

Market cap
28.78B
Enterprise value
28.92B
Trailing P/E
52.80
Forward P/E
41.31
PEG ratio
3.24
Price / sales
8.47
Price / book
9.71
EPS (TTM)
7.81
Beta
0.00
Dividend yield
0.25%
Payout ratio
11.14%
Profit margin
18.81%
Revenue (TTM)
3.40B
Revenue growth
8.70%
Free cash flow
326.94M
Total cash
464.10M
Total debt
305.00M
Return on equity
21.23%
Shares outstanding
69.78M
Short % of float
3.38%
50-day average
366.43
200-day average
312.69

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 442.20 +7.2% upside
Target (low)
340.00
Target (mean)
442.20
Target (high)
500.00
Ratings (0m) 16 15 buy · 0 hold · 1 sell
  • Strong buy3
  • Buy12
  • Hold0
  • Sell0
  • Strong sell1

Next earnings

Feb 11, 2027

Expected Feb 11, 2027. Consensus EPS estimate 2.27.

Earnings history

Financials — quick view

All financials
WST Revenue — quarterly 874.50M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
WST Net income — quarterly 214.00M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
WST EPS — quarterly 3.04
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

WST recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 11, 2027Dec 30, 20262.26———
Oct 29, 2026Sep 30, 20262.202.66+0.46+20.91%
Jul 23, 2026Jun 30, 20262.082.37+0.29+13.94%
Apr 23, 2026Mar 31, 20261.682.13+0.45+26.79%
Feb 12, 2026Dec 31, 20251.832.04+0.21+11.48%
Oct 23, 2025Sep 30, 20251.681.96+0.28+16.67%

Upgrades / downgrades

WST analyst upgrades and downgrades
DateFirmActionFromTo
Oct 30, 2026BarclaysmainOverweightOverweight
Oct 30, 2026Evercore ISI GroupmainOutperformOutperform
Oct 13, 2026TD CowenmainBuyBuy
Oct 7, 2026BarclaysmainOverweightOverweight
Sep 22, 2026Morgan StanleyupEqual-WeightOverweight
Sep 9, 2026UBSmainBuyBuy

About West Pharmaceutical Services, Inc.

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.

Sector
Healthcare
Industry
Medical Instruments & Supplies
Country
United States

News

Your note

Sign in to keep a note on WST — it syncs with the Stock Master app.

Insider holders

WST insider holders
InsiderRelationLatest transactionDateShares held
BIRKETT BERNARD JOHNChief Financial OfficerConversion of Exercise of derivative securityFeb 17, 20257,520
BUTHMAN MARK ADirectorStock Award(Grant)May 3, 202644,308
FAVORITE ANNETTE FOfficerSaleSep 14, 202621,817
FEEHERY WILLIAM F.DirectorStock Award(Grant)May 3, 202632,519
GREEN ERIC MARKChief Executive OfficerConversion of Exercise of derivative securityFeb 17, 2026175,418
HOFMANN THOMAS WDirectorStock Award(Grant)May 5, 202544,637

Institution ownership

WST institution ownership
Holder% heldSharesValueReported
Blackrock Inc.9.45%6,651,7842.74BJun 29, 2026
Vanguard Capital Management LLC6.56%4,613,1341.90BJun 29, 2026
Vanguard Portfolio Management LLC5.71%4,015,7661.66BJun 29, 2026
FMR, LLC5.08%3,574,8161.47BJun 29, 2026
State Street Corporation4.76%3,348,6981.38BJun 29, 2026
Artisan Partners Limited Partnership3.43%2,411,792994.62MJun 29, 2026

Fund ownership

WST fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.19%2,242,860924.96MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.60%1,830,358754.84MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund2.18%1,530,738631.28MJun 29, 2026
Fidelity Contrafund1.59%1,120,323462.02MAug 30, 2026
VANGUARD INDEX FUNDS-Vanguard Growth Index Fund1.34%940,525387.87MJun 29, 2026
iShares Trust-iShares Core S&P 500 ETF1.33%937,921386.80MSep 29, 2026
Advertisement